Cervical cancer is responsible for 10-15% of cancer-related deaths in women worldwide 1, 2 . The aetiological role of infection with highrisk human papilloma viruses (HPVs) in cervical carcinomas is well established 3 . Previous studies have also implicated somatic mutations in PIK3CA, PTEN, TP53, STK11 and KRAS 4-7 as well as several copynumber alterations in the pathogenesis of cervical carcinomas 8, 9 . Here we report whole-exome sequencing analysis of 115 cervical carcinomanormal paired samples, transcriptome sequencing of 79 cases and whole-genome sequencing of 14 tumour-normal pairs. Previously unknown somatic mutations in 79 primary squamous cell carcinomas include recurrent E322K substitutions in the MAPK1 gene (8%), inactivating mutations in the HLA-B gene (9%), and mutations in EP300 (16%), FBXW7 (15%), NFE2L2 (4%), TP53 (5%) and ERBB2 (6%). We also observe somatic ELF3 (13%) and CBFB (8%) mutations in 24 adenocarcinomas. Squamous cell carcinomas have higher frequencies of somatic nucleotide substitutions occurring at cytosines preceded by thymines (Tp*C sites) than adenocarcinomas. Gene expression levels at HPV integration sites were statistically significantly higher in tumours with HPV integration compared with expression of the same genes in tumours without viral integration at the same site. These data demonstrate several recurrent genomic alterations in cervical carcinomas that suggest new strategies to combat this disease.
. The aetiological role of infection with highrisk human papilloma viruses (HPVs) in cervical carcinomas is well established 3 . Previous studies have also implicated somatic mutations in PIK3CA, PTEN, TP53, STK11 and KRAS [4] [5] [6] [7] as well as several copynumber alterations in the pathogenesis of cervical carcinomas 8, 9 . Here we report whole-exome sequencing analysis of 115 cervical carcinomanormal paired samples, transcriptome sequencing of 79 cases and whole-genome sequencing of 14 tumour-normal pairs. Previously unknown somatic mutations in 79 primary squamous cell carcinomas include recurrent E322K substitutions in the MAPK1 gene (8%), inactivating mutations in the HLA-B gene (9%), and mutations in EP300 (16%), FBXW7 (15%), NFE2L2 (4%), TP53 (5%) and ERBB2 (6%). We also observe somatic ELF3 (13%) and CBFB (8%) mutations in 24 adenocarcinomas. Squamous cell carcinomas have higher frequencies of somatic nucleotide substitutions occurring at cytosines preceded by thymines (Tp*C sites) than adenocarcinomas. Gene expression levels at HPV integration sites were statistically significantly higher in tumours with HPV integration compared with expression of the same genes in tumours without viral integration at the same site. These data demonstrate several recurrent genomic alterations in cervical carcinomas that suggest new strategies to combat this disease.
The prevention of cervical cancer by Pap smear-based screening and treatment programs has been largely successful in resource-rich countries. However, cervical cancer is the second most common cause of cancerrelated deaths in women in developing countries, in which many patients are diagnosed at advanced stages of disease with limited treatment options and poor prognosis 1 . Recent advances in targeted therapy against specific somatic alterations have transformed the management of cancers in general 10 , and the discovery of new therapeutic targets in cervical cancer could improve upon current strategies to combat cervical carcinomas.
To provide comprehensive data on the landscape of genomic aberrations that contribute to cervical cancer, we investigated a cohort that included 100 patients from Norway and 15 patients from Mexico (Supplementary Notes 1-7). We performed exome sequencing of 193,094 exons, covering a median of 34.2 megabases (Mb) at a median of 893 (range: 56-1223) coverage for tumour samples and 883 (range: 69-1223) coverage for normal samples, followed by calling of somatic mutations using the MuTect algorithm 11 , and identified a total of 17,795 somatic mutations across the entire data set, including 11,419 missense, 936 nonsense, 4,643 silent, 219 splice site and 29 translation start site mutations, as well as 401 deletions and 131 insertions.
The aggregate nonsilent mutation rate across the data set was 3.7 per Mb. However, squamous cell carcinomas had a higher rate of nonsilent mutations (4.2 mutations per Mb) than adenocarcinomas (1.6 mutations per Mb) (Wilcoxon P 5 0.0095). The clinical, pathological, epidemiological and mutational characteristics of the tumours are summarized in Supplementary Figs 1-6 , Supplementary Tables 1-5 and Supplementary Notes 8 and 9 .
Hierarchical clustering of all 115 tumours on the basis of mutational context revealed that most tumours were characterized by previously described 12 mutational signatures: with predominantly Tp*C-to-T/G mutations and *CpG-to-T mutations ( Fig. 1 and Supplementary Fig. 4 ). Tp*C mutations were present at a relative frequency of .0.5 in 53 (46%) tumours, and the relative frequency of Tp*C mutations was positively correlated with mutation rates, especially in squamous cell carcinomas ( Fig. 1 , Supplementary Note 8 and Supplementary Fig. 5 ). In addition, 5,648 (54%) of the 10,328 nonsilent mutations observed in squamous cell carcinomas were Tp*C-to-T/G mutations.
We performed mutation significance analyses on 79 squamous cell carcinomas and 24 adenocarcinomas. Genes were determined to be significantly mutated if recurrent mutations were found in that gene at a false discovery rate of q , 0.1 after correction for multiple hypothesis testing, as described previously 13 (Supplementary Note 6). Details of candidate mutation validation are presented in Supplementary Figs 6 and 7.
As expected, recurrent mutations in PIK3CA, PTEN and STK11 were present in 14%, 6% and 4%, respectively, of 79 squamous cell carcinomas (Table 1 ). In addition, we found significantly recurrent mutations in EP300 (16%), FBXW7 (15%), HLA-B (9%), MAPK1 (8%) and NFE2L2 (4%), here reported for the first time, to our knowledge, in primary squamous cell cervical carcinomas (Table 1, Fig. 1, Supplementary Table 6 and Supplementary Fig. 8 ). In addition, TP53 (9%) and ERBB2 (5%) were found to be significantly mutated in analyses focused only on genes previously reported as mutated in the COSMIC database (http:// cancer.sanger.ac.uk/cancergenome/projects/cosmic) ( Supplementary  Table 8a ). Interestingly, three out of the six ERBB2 mutations (S310F, S310Y and V842I; Supplementary Fig. 8 ) are known oncogenic driver mutations and in vitro therapeutic targets in lung 14 and breast cancer 15 . Somatic MAPK1 mutations were observed in 6 out of 79 squamous cell carcinomas of the cervix (7%), each involving a G-to-A transition resulting in recurrent E322K mutations in four individuals, and E81K and E220K mutations in one individual each (Fig. 2) . To our knowledge, this is the first report of recurrent mutations of MAPK1 in primary human cancer, although the MAPK1 E322K mutation has been reported in an oropharyngeal carcinoma cell line 16 and scattered unpublished reports are summarized in COSMIC. The recurrent site-specific MAPK1 mutations and the known role of the MAPK signalling pathway in cancer 17 suggest the possibility that mutant MAPK1 may exert oncogenic activity.
We observed EP300 and FBXW7 mutations in our data set, similar to recent reports in endometrial and head and neck cancers 18, 19 . Thirteen Indel, insertions or deletions; null, nonsense, frameshift or splice-site mutations; q, q value, false discovery rate (Benjamini-Hochberg procedure).
* Genes with mutations observed in only squamous cell carcinomas.
{ Genes with mutations observed in only adenocarcinomas.
{ Genes with a majority of mutations occurring in squamous cell carcinomas.
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out of 15 nonsilent EP300 mutations are novel in cancer, with eight of these (including two nonsense) residing in the histone acetyltransferaseand bromo-domains required for EP300 activity 20 ( Fig. 2 ). In addition, there were two truncating mutations at residues S255 and Q458 in EP300. The FBXW7 gene also had two novel truncating mutations at residues Q631 and R678, with ten other mutations residing in the WD40 domains required to form the scaffold for the Skp1-Cul1-Fbox protein complex 21 . Furthermore, all four NFE2L2 mutations (W24C, R34P, R34Q and E82D) are in the domain required for interacting with its negative regulator, KEAP1 (ref. 22) (Fig. 2) , consistent with similar findings in lung squamous cancers 23 . Interestingly, mutations in these genes (FBXW7, EP300, MAPK1, NFE2L2) occur largely in a non-overlapping pattern in our data set ( Fig. 1 and Supplementary Fig. 6b ). These observations suggest that epigenetic regulation and the oxidative stress response may have important roles in cervical cancer pathogenesis.
We found four missense and three frameshift mutations in the HLA-B gene encoding the histocompatibility leukocyte antigen HLA-B ( Fig. 2 and Table 1 ). In addition, there were somatic mutations in other genes involved in antigen presentation, including splice site, nonsense and frameshift mutations in HLA-A, a gene previously reported as mutated in squamous cell carcinomas of the lung 23 , and in the b 2 -microglobulin (B2M) gene (Supplementary Fig. 8 and Supplementary Table 6 ). All mutations in these three genes were within the antigen-presenting domains of each respective protein 24 . Intriguingly, pathway analyses also revealed that the most significantly mutated gene set in squamous cell carcinomas involves immune response genes in the interferon-c signalling pathway, including mutations in IFNG and JAK2 (Supplementary Table 9a ). Together, these data highlight the potential significance of the synergy between HPV infection and an altered immune response in the pathogenesis of squamous cell carcinomas of the cervix.
We also investigated a smaller subset of 24 adenocarcinomas. Our analysis revealed the ELF3 (13%) and CBFB (8%) genes as recurrently mutated at q , 0.1 (Fig. 2, Table 1 , Supplementary Fig. 8 and Supplementary Table 7 ). In addition, PIK3CA (16%) and KRAS (8%) were found to be significantly mutated in analyses focused only on genes previously reported as mutated in the COSMIC database (Supplementary Table 8b ), consistent with previous reports 6 . Furthermore, gene set analyses revealed that the PIK3CA/PTEN pathway was significantly recurrently mutated across the adenocarcinoma subset (Supplementary Table 9b ).
The ELF3 mutations in the adenocarcinomas involve frameshift insertional events at amino acid positions 255, 330 and 350. ELF3 (E74-like factor-3) encodes a member of the ETS transcription factor family that is expressed and upregulated in epithelial cancers, and is both a regulator and downstream effector of the ERBB2 signalling pathway 25 . Interestingly, ELF3-mutated tumours have higher gene expression levels than ELF3 wild-type tumours ( Supplementary Fig. 9 ).
The spectrum of somatic copy-number alterations, rearrangements, gene expression profiles, HPV integration and other genomic events observed in this cohort are documented in Supplementary Notes 10-14, Supplementary Tables 10-21 and Supplementary Figs 10-30 . HPV integration sites were defined by the presence of least six chimaeric read pairs, derived from RNA sequencing (RNA-seq) data, in which the pairmate of an HPV sequence read mapped to the human genome (Supplementary Note 7). As expected, HPV integration sites were found within or in close proximity to several fragile sites (Supplementary Note 11) as well as previously reported genes [26] [27] [28] [29] including MYC, ERBB2, TP63, FANCC, RAD51B and CEACAM5 (Supplementary Table 14) .
HPV integration occurred closer to amplified regions than expected by chance (Mann-Whitney P , 2.2 3 10
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; Fig. 3a) , with 21 (41%) of 51 integration sites overlapping with amplified regions, supporting the hypothesis that viral integration may trigger genome amplification 30 . In general, viral integration was localized to one locus in most tumours investigated, and most of the integration sites were observed only in one tumour each (Supplementary Table 14 ). In addition, many of the genes involved in the integration events are members of cellular pathways known to have important roles in cancer (Supplementary Table 15 We also observed that gene expression levels at sites of HPV integration were significantly higher in tumours with HPV integration compared with the expression levels of the same genes across the other tumours without integration at that site (P , 2.2 3 10
; Fig. 3b and Supplementary Figs 22-24) . For some integration sites, including MYC, ERBB2, GLI2, TNIK, NR4A2, PROX1, EIF2C2, FAM179B and SERPINB4, high gene expression levels were associated with copy-number gains ( Fig. 3c and Supplementary Fig. 25 ). Conversely, there were no copynumber changes at several other highly expressed integration sites including RPS6KB1, MAFA, PARN, EGFL7, SNIP1, POC1B and BCL11B (Fig. 3c, Supplementary Fig. 26 and Supplementary Notes 11E, F), supporting the hypothesis that the increased expression of these genes may be driven in part by integrated viral promoter(s) 27 . In summary, this study has demonstrated relationships between recurrent somatic mutations, copy-number alterations, gene expression and HPV integration in cervical carcinomas. We report significantly recurrent somatic mutations in the MAPK1 gene in squamous cell cervical cancers, to our knowledge the first such report in human cancers. In addition, we found evidence of potential ERBB2 activation by somatic mutation, amplification and HPV integration, suggesting that some cervical carcinoma patients could potentially be considered as candidates for clinical trials of ERBB2 inhibitors. Furthermore, our data suggest that alterations in immune response genes may synergize with HPV infection in the pathogenesis of squamous cell carcinomas. Finally, our data suggests that the association between HPV integration and increased expression of adjacent genes is a widespread phenomenon in primary cervical carcinomas.
METHODS SUMMARY
Following Institutional Review Board approvals and informed consent, nucleic acids were extracted from resected tumour tissue and normal peripheral blood in 115 patients. Exome, whole genome and cDNA sequencing was performed for 115, 14 and 79 patients, respectively, on Illumina HiSeq 2000 instruments. A flowchart of the entire analysis procedure can be found in Supplementary Fig. 1 . A detailed description of the materials, analyses and validation is found in the Methods section.
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METHODS
Sample preparation. All samples were obtained under Institutional Review Board approval and with documented informed consent. Surgically resected tumours or biopsies were snap frozen in liquid nitrogen and stored at 280 uC. Genomic DNA and RNA were extracted from tumours found by frozen section investigations to have .40% malignant epithelial cell component. A detailed description of sample collection is found in Supplementary Note 1. Nucleic acid was extracted using standard protocols described in Supplementary Note 2. Sequence data generation. DNA from 115 tumour-normal paired samples was subjected to Agilent Sure-Select Human All Exon v2.0 based hybrid selection 31 followed by exome library construction for Illumina sequencing, and 14 pairs for whole genome library construction; complementary DNA from 79 samples was subjected to transcriptome library construction, according to standard methods. Twelve tumour-normal pairs were sequenced with all three types of libraries. All libraries were sequenced with the Illumina HiSeq 2000 instrument (Supplementary Note 4). Exome sequencing was performed using a hybrid capture of 193,094 exon targets from 18,862 coding genes. Reads were aligned to human genome build GRCh37 using a Burrows-Wheeler aligner 32 . Data from the Illumina HiSeq were converted into BAM files 33 (http://samtools.sourceforge.net/SAM1.pdf) for each sample, using Picard (http://picard.sourceforge.net/) (Supplementary Note 6A). Variant calling and significance analysis. All variant calls and significance analysis were obtained using the standard Cancer Genome Analysis Pipeline [34] [35] [36] [37] [38] with some modifications detailed in Supplementary Note 6B. Cross-individual contamination was estimated using ContEst 39 with both single nucleotide polymorphism (SNP) Array (Supplementary Note 5) and sequencing data as input. Somatic single nucleotide variant (sSNV) and indel calls were generated using MuTect 11, [34] [35] [36] and Indelocator [34] [35] [36] , respectively, for all complete exome tumour-normal pairs. Variants were mapped to genes and transcripts using Oncotator (http://www. broadinstitute.org/oncotator), as well as being annotated with useful information such as overlapping COSMIC 40 records. D-ToxoG (http://www.broadinstitute. org/cancer/cga/dtoxog) was used to filter mutations generated by a sequencing artefact that was discovered during this project. Significantly mutated genes and gene sets (Supplementary Note 9) were identified by MutSig2.0 (ref. 13 ) on the basis of sSNV and indel calls. Mutation rate calculations were also provided by MutSig2.0. Rearrangements were identified using dRanger 37 running on data generated by whole genome sequencing (WGS) of 14 tumour-normal pairs (Supplementary Note 13A), on the basis of read pairings with unexpected distance or orientation. Somatic copy-number alterations, both broad and focal, were identified with the GISTIC 2.0 (refs 35, 36) tool, using segments identified from exome sequencing data (Supplementary Note 6B) as input (Supplementary Note 10A). Overlap between copy-number alterations and somatic nonsilent mutations, for a subset of significantly mutated genes, are reported in Supplementary Note 10D and Supplementary Fig. 14. UnifiedGenotyper 41, 42 was used to identify germline mutations in genes in the Fanconi anaemia pathway and TERC, as reported in Supplementary Notes 14B, C. ABSOLUTE 43 was used to generate purity and ploidy estimates for tumour samples where SNP Array data was available (Source Data File 1). Variant validation. Two validation approaches were used in this study. The first was to re-sequence mutations in significant genes. Libraries were constructed with 200 base pair flanks around key mutations in significant genes and sequenced using Illumina MiSeq. Manual validation was performed by examining mutations in the resulting BAM files. Mutations were considered validated if supported by five or more reads. The second validation approach was to compare exome sSNV calls against the corresponding WGS and/or RNA-seq calls where available. Mutations were considered validated if the alternate allele was seen in at least two reads and the calculated power was 80% or higher. These two approaches are detailed in Supplementary Note 6D. Owing to the variable nature of human leukocyte antigen (HLA) genes 44 , mutations in HLA-A and HLA-B were validated manually using the procedure detailed in Supplementary Note 6E. Hierarchical clustering of mutation signatures. Hierarchical clustering of all 115 samples, by nucleotide mutational context, using the heatmap.2 function from the gplots library (http://cran.r-project.org/web/packages/gplots/index.html) implemented in R 2.15.1 was performed. Mutation counts were scaled within each sample (that is, converted to fraction of mutations corresponding to each category) and clustered using Ward's minimum variance method 45 . Analysis of associations between mutation signature clusters and epidemiological factors (age, histology, geography, tumour grade and smoking status) was performed using Kruskal-Wallis, for continuous factors (age), and Fisher's exact test, for discrete factors (histology, geography, tumour grade and smoking status). A P-value threshold of 0.05 was used to decide association for all statistical testing. A detailed description and results can be found in Supplementary Note 8A. For display purposes in Fig. 1 , Tp*CpG mutations (which belong to both of the Tp*C and *CpG groups) are redistributed proportionately to each group, on the basis of the relative frequencies of the other Tp*C and*CpG mutations in each tumour. Hierarchical clustering of copy-number variants. Copy-number profiles, generated by GISTIC 2.0, were clustered into three categories. Each category was tested for association with tumour grade and histology using Fisher's exact test and a P-value threshold of 0.05 (Supplementary Note 10B) . Gene expression analysis. Gene expression was measured using Cufflinks and cuffdiff 46 from the RNA-seq data and fragments per kilobase of exon per million fragments mapped (FPKM) was obtained. As non-transcribed genes tend to have more artefactual mutations 37, 38, 47, 48 , genes with low expression values (FPKM , 1) were filtered from significantly mutated gene lists produced by MutSig2.0 (Supplementary Note 6C). Genes with detected HPV integration sites were further analysed for increased expression levels by ranking the expression levels of relevant genes for each sample (Supplementary Notes 11E, F and G) . Consensus clustering was performed on the RNA-seq-derived gene expression data from 79 tumours, using ConsensusClusterPlus 49 . This analysis was run, using 1,000 resampling iterations and a maximum of 25 clusters, on the 5,000 genes with the largest deviation of FPKM scores across all patients. A final k value was chosen based on minimum threshold of change as k was increased (Supplementary Note 12) . The correlative relationships between copy-number variation and gene expression data were evaluated using Pearson correlation (Supplementary Note 10C) . Fusion analysis in transcriptome. RNA-seq data was analysed for fusion events by identifying inter-chromosomal chimaeric read pairs or exon-exon read pairs separated by at least 1 Mb, with pairmates in the appropriate coding strand orientation. Unmapped reads spanning the putative fusion junction were also identified. High-confidence fusion events are defined as having at least three reads mapped to a junction fusion (Supplementary Note 13B). HPV typing. HPV typing was done by two multiplex HPV DNA PCR methods: the fluorescent f-HPV assay 50 and the mass-spectrometry-based HPV PCRMassArray 51, 52 (Supplementary Note 3A). In addition, PathSeq 53 was used to generate HPV typing information from RNA-seq data (Supplementary Note 3B). HPV genome integration analysis. PathSeq 53 was used to identify sites of HPV genome integration in the cohort (Supplementary Notes 7 and 11A). Integration sites were identified using paired reads where one read aligned to the HPV genome (using NCBI viral databases) and the other to the human genome (Supplementary Note 11C). Validation of a recurrent integration site, in RAD51B, was performed by RT-PCR using primers targeting the junctions of specific HPV-RAD51B chimaeric reads in three tumours (Supplementary Note 11B). In cases in which the tumour with an integration site also had SNP array data, the distance between the integration site and the nearest copy-number amplification was calculated. SNP Array data were used to identify amplifications. To evaluate co-occurrence of integration sites and copy-number amplifications, data for a null model was created by simulating integration sites at uniformly distributed locations in the genome and assigning the simulated integration sites to random samples. The distribution of distances between the simulated integration sites and nearest copynumber amplification compared to the true distribution of distances (Supplementary Note 11D). In Fig. 3a , the true data (top histogram) was compared to distances generated from 100,000 permutations of randomly distributed integration sites across the genome with respect to the observed amplifications (bottom histogram). Overlapping amplification/integration sites have a distance of 0. Integration sites without amplification on the same chromosome were assigned a distance of the longest chromosome plus 1 (the bars on the right). MSigDB 54 was queried to evaluate whether the HPV integration sites co-occur in pathways with known roles in cancer (Supplementary Note 11H). Epidemiological analysis for mutation rates. The statistical significance of mutation rate across histological types was corrected for the epidemiological factors: age (continuous), geography (discrete), tumour grade (discrete) and smoking status at diagnosis (discrete). The Fisher's exact test (for discrete factors) and the Wilcoxon test (for continuous factors) were run across histology (squamous cell and adenocarcinomas only). A P-value threshold of 0.05 was used to decide association for all statistical testing. For factors for which an association was found with histology and mutation rate, we used a linear regression model to test whether histology was an independent predictor of mutation rate (Supplementary Note 8B). Analysis of miscellaneous genes and pathways of interest. Additional analysis of notable gene sets and pathways were performed using different techniques depending on the task. APOBEC gene family members are known to deaminate cytosine residues in the Tp*C context 55, 56 . The mutational characteristics of these genes were investigated and results reported in Supplementary Note 14A. The Fanconi anaemia pathway has been implicated in suppressing HPV infection. Mutated genes in the Fanconi anaemia pathway were identified from the somatic single nucleotide variant, somatic indel, and germline calls (Supplementary Note 14B) . TERC has been identified as a marker for genomic instability and copy number gain. Therefore, we identified copy-number variations encompassing the TERC
